J&J, Legend Report Carvykti Cut Death Risk by 45% in Multiple Myeloma Study

Seeking Alpha17:18 ET

J&J Releases Encouraging Data on Talvey Combination Therapies

Seeking Alpha16:42 ET

Johnson & Johnson's CARVYKTI Is The First And Only Cell Therapy To Significantly Extend Overall Survival Versus Standard Therapies For Patients With Multiple Myeloma As Early As Second Line; 45% Reduction In Risk Of Death Achieved With CARVYKTI After...

Benzinga16:33 ET

Home Depot's Options: A Look at What the Big Money Is Thinking

Benzinga15:17 ET

Walmart Analyst Ratings

Benzinga14:35 ET · Ratings

Hurricane Helene Update: 28 Dead, Power Outages, Insurance Damages And More

Benzinga14:19 ET